CommercialCoverageLow impact
08.01.93e, Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer Disease
Independence Blue Cross·Neurology, Internal Medicine, Geriatrics·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.01.93e regarding monoclonal antibodies for Alzheimer's disease treatment has been reissued with an effective date of March 5, 2025. This is a commercial policy update that may affect coverage criteria or billing requirements for Alzheimer's treatments using monoclonal antibodies.
Action Required
By March 5, 2025: Review updated policy 08.01.93e for any changes to coverage criteria or documentation requirements for monoclonal antibody treatments for Alzheimer's disease. Billing team should access the full policy at the provided URL to identify specific billing and authorization changes that may affect claim processing.